Continuous Glucose Monitor (CGM) prior authorization
Customize your policy alerts
Sign up for all Capital Bluecross policy alerts
Know when Capital Bluecross releases new policies or updates existing guidance.
Monitor payer policy activity
Defines prior authorization requirements for Continuous Glucose Monitors (CGMs) for Capital Blue Cross beneficiaries, including clinical criteria, preferred devices, and approval duration. Applies to providers requesting coverage for CGM systems for members covered by Capital Blue Cross.
No material clinical or coverage changes in this revision.
Coverage Criteria for Continuous Glucose Monitors (CGMs)
Initial Approval
Covered when ALL of the following are met:
Root
- 1. Diabetes diagnosis: The beneficiary has diabetes mellitus
2. Treatment / Hypoglycemia criteria
- 2.A Insulin treated: Beneficiary is insulin treated
2.B Non-insulin treated with hypoglycemia
- 2.B.i Recurrent level 2 events: History of recurrent (more than one) level 2 hypoglycemic events AND documentation of BOTH: (a) at least ONE of: glucose values for qualifying event(s) < 54 mg/dL OR classification of the episode(s) as level 2 OR BGM logs reflecting the specific qualifying events (< 54 mg/dL); AND (b) documentation of more than one prior medication adjustment and/or modification to the treatment plan prior to the most recent level 2 event< 54 mg/dL (3.0 mmol/L)
- 2.B.ii Level 3 event: History of at least one level 3 hypoglycemic event characterized by altered mental and/or physical state AND documentation of BOTH: (a) at least ONE of: glucose values for the qualifying event(s) < 54 mg/dL OR classification as level 3 OR BGM log reflecting the specific qualifying event (< 54 mg/dL); AND (b) indication that third-party assistance was required for treatment of hypoglycemia< 54 mg/dL (3.0 mmol/L)
- 3. Prescriber visit: Either the prescriber documents an in-person or telehealth visit within 6 months prior to ordering confirming criteria 1–2 are met, OR if previously approved, the prescriber documents a visit confirming continued adherence and use of the CGM
- 4. Preferred device requirement: Either the requested CGM is a preferred CGM OR the prescriber has indicated the beneficiary failed or has limitations of use of a preferred CGM (trial of one preferred CGM required before non-preferred)
Non-preferred Continuous Glucose Monitor (CGM) products require prior authorization. Approval for a non-preferred CGM will only be granted after the beneficiary has trialed ONE preferred CGM system (examples: Dexcom or FreeStyle) unless the prescriber documents failure or limitations of the preferred device. When prior authorization is required, approval is contingent on meeting all clinical criteria in the evaluation section and, when approved, coverage is authorized for 12 months.
The preferred agents listed for the CGM program include Dexcom G6, Dexcom G7, FreeStyle Libre, FreeStyle Libre 2, and FreeStyle Libre 3. Prior authorization (PA) applies only to non-preferred products; prescribers requesting a non-preferred CGM must indicate that a preferred product was tried and either failed or had limitations that justify the non-preferred request.
Requests for CGM coverage that do not document a diagnosis of diabetes mellitus are not supported. Similarly, requests are not supported when the beneficiary does not meet the required treatment or hypoglycemia criteria — specifically, either being insulin treated or meeting the documented hypoglycemia thresholds and history described in the criteria (recurrent level 2 events or at least one level 3 event with required documentation).
Ensure submitted requests include the required clinical documentation (diagnosis and evidence of qualifying treatment or hypoglycemic events) because absence of these items is a primary reason for denial.
Coding and Identifiers
| 97202012026200 | Dexcom G6 receiver / Dexcom G7 receiver / FreeStyle Libre reader / FreeStyle Libre 2 Reader / FreeStyle Libre 3 Reader / Guardian Real-Time replacement monitor / Guardian Real-Time, Real-Time Pediatric replacement monitor |
| 97202012066300 | Dexcom G6 transmitter / Guardian Link 3 transmitter / Guardian 4 transmitter kit / Minilink Real Time transmitter / Minimed 630G Guardian Press Starter transmitter kit / Paradigm Real-Time transmitter |
| 97202012046300 | Dexcom G6 sensor / Dexcom G7 sensor / FreeStyle Libre sensor / FreeStyle Libre 2 Sensor / FreeStyle Libre 2 Plus Sensor / FreeStyle Libre 3 Sensor / FreeStyle Libre 3 Plus Sensor / Enlite Glucose sensor / Guardian Sensor 3 / Guardian 4 sensor / Simplera Sync Sensor |
Provider Actions, Prior Authorization & Documentation
Prior authorization required for non-preferred CGMs
Prior authorization is required for non-preferred continuous glucose monitor (CGM) products. Approval is granted only when all listed clinical criteria are met; length of approval is 12 months.
Preferred CGM trial required before non-preferred
The beneficiary must trial ONE preferred CGM system (Dexcom OR FreeStyle) before a non-preferred CGM will be approved. If the prescriber requests a non-preferred device without that trial, the prescriber must indicate failure or limitations of the preferred CGM.
Document qualifying hypoglycemic events
Include documentation of qualifying hypoglycemic events: glucose values less than 54 mg/dL (3.0 mmol/L), classification of events as level 2 or level 3, or incorporation of the beneficiary's BGM testing log showing the specific qualifying events.
Denial triggers for insufficient documentation or unmet criteria
Requests may be denied if the beneficiary does not have documentation of diabetes or does not meet the required clinical criteria (e.g., not insulin-treated or lacking qualifying hypoglycemia documentation), or if required prescriber visit documentation within six months is not provided.
- No diabetes mellitus diagnosis documented
- Does not meet treatment/hypoglycemia criteria (insulin-treated OR qualifying level 2/3 events documented)
- No in-person or telehealth visit documented within 6 months prior to ordering
Definitions
Background
Continuous Glucose Monitors (CGMs) measure interstitial glucose continuously and provide information that complements HbA1c and self-monitoring of blood glucose. CGMs enable assessment of time in range, detection of glucose variability, and identification of hypoglycemia trends that single-point measurements may miss. Real-time CGM (rtCGM) systems can provide near real-time glucose data and alerts for impending hypo- or hyperglycemia, while intermittently viewed CGM (iCGM) systems require the user to scan the sensor to view glucose data.
Clinical justification for CGM use includes situations where beneficiaries have diabetes mellitus and either require insulin therapy or have a documented history of clinically significant hypoglycemia. The policy uses level 2 hypoglycemia (glucose <54 mg/dL [3.0 mmol/L]) and level 3 hypoglycemia (events requiring third-party assistance) as qualifying event thresholds that support CGM coverage when properly documented.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.